Nitro reduction as an electronic switch for bioreductive drug activation

Oncology Research

Volumn 9, Issue 6-7, 1997, Pages 357-369

  Sum, Bromvyn G ^a   Denny, William A ^a   Wilson, William R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

ADEPT; Bioreductive drugs; GDEPT; Hypoxia; Nitro reduction; Nitrogen mustard

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; NITRO DERIVATIVE; PRODRUG; RADIOSENSITIZING AGENT;

ANIMAL; BIOTRANSFORMATION; ELECTROCHEMISTRY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; REVIEW;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; ELECTROCHEMISTRY; HUMANS; NITRO COMPOUNDS; OXIDATION-REDUCTION; PRODRUGS; RADIATION-SENSITIZING AGENTS;

EID: 0031306972     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Rockwell, S.; Sartorelli, A. C.; Tomasz, M.; Kennedy, K. A. Cellular pharmacology of quinone bioreductive alkylating agents. Cancer Metastasis Rev. 12:165-176; 1993.
2. Workman, P.; Stratford, I. J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12:73-82; 1993.
3. Brown, J. M.; Sum, B. G. Hypoxia specific cytotoxins in cancer therapy. Semin. Radiât. Oncol. 6:22-36; 1996.
4. Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 74(Suppl.XXVlI):S32-S38; 1996.
5. Gatenby, R. A.; Kessler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H. Oxygen distribution in squamous cell carcinoma métastases and its relationship to outcome of radiation therapy. Int. J. Radial. Oncol. Biol. Phys. 14:831-838; 1988.
6. Hockel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Baubmann, E.; Mitze, M.; Knapstein, P. G.; Vaupel, P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 26:45-50; 1993.
7. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygénation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 41:31-39; 1996.
8. Overgaard, J.; Horsman, M. R. Modification of hypoxiainduced radioresistance in tumors by the use of oxygen and sensitizers. Semin. Radiât. Oncol. 6:10-21; 1996.
9. Tannock, I. Cell kinetics and chemotherapy: A critical review. Cancer Treat. Rep. 62:1117-1133; 1978.
10. Hughes, C. S.; Shen, J. W.; Subjeck, J. R. Resistance to etoposide induced by three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res. 49:4452-4454; 1989.
11. Wilson, W. R.; Denny, W. A. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In: Dewey, W. C.; Edington, M.; Fry, R. J. M.; Hall, E. J.; Whitmore, G. F., eds. Radiation research, a twentieth-century perspective. San Diego: Academic Press; 1992:796-801.
12. Stone, H. B.; Brown, J. M.; Phillips, T. L.; Sutherland, R. M. Oxygen in human tumors: Correlations between methods of measurement and response to therapy. Radiât. Res. 136: 422-434; 1993.
13. Raleigh, J. A.; Dewhirst, M. W.; Thrall, D. E. Measuring tumor hypoxia. Semin. Radiât. Oncol. 6:37-45; 1996.
14. Niculescu-Duvaz, I.; Springer, C. J. Antibody-directed enzyme prodrug therapy (ADEPT): A targeting strategy in cancer chemotherapy. Curr. Med. Chem. 2:687-706; 1995.
15. Bagshawe, K. D. Antibody-directed enzyme prodrug therapy: A review. Drug Dev. Res. 34:220-230; 1995.
16. Melton, R. G.; Knox, R. J.; Connors, T. A. Antibodydirected enzyme prodrug therapy (ADEPT). Drugs Future 21: 167-181; 1996.
17. Huber, B. E.; Richards, C. A.; Austin, E. A. VDEPT-an enzyme prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv. Drug Delivery Rev. 17:279-292; 1995.
18. Anlezark, G.; Melton, R.; Sherwood, R.; Knox, R.; Friedlos, F.; Palmer, B.; Wilson, W.; Denny, W. Nitroreductase substrates as potential prodrugs for ADEPT. Br. J. Cancer 69(SuppI. XX1):57; 1994.
19. Anlezark, G. M.; Melton, R. G.; Sherwood, R.; Wilson, W. R.; Denny, W. A.; Palmer, B. D.; Knox, R. J.; Friedlos, F.; Williams, A. Bioactivation of dinitrobenzamide mustards by an £. co//B nitroreductase. Biochem. Pharmacol. 50:609-618; 1995.
20. Hay, M. P.; Denny, W. A. Antibody-directed enzymeprodrug therapy (ADEPT). Drugs Future 21:917-931; 1996.
21. Hall, E. J.; Roizin-Towle, L. Hypoxie sensitizers: Radiobiological studies at the cellular level. Radiology 117:453-457; 1975.
22. Mohindra, J. K.; Rauth, A. M. Increased cell killing by metronidazole and nitrofurazone of hypoxic compared to aerobic mammalian cells. Cancer Res. 36:930-936; 1976.
23. Ehlhardt, W. J.; Goldman, P. Thiol-mediated incorporation
24. of radiolabel from l-[14C]-methyl-4-phenyl-5-nitrosoimidazoleinto DNA. Biochem. Pharmacol. 38:1175-1180; 1989.
25. Noss, M. B.; Panicucci, R.; McClelland, R. A.; Rauth, A. M. l-Methyl-2-nitrosoimidazole: Cytotoxic and glutathione depleting capabilities. Int. J. Radiât. Oncol. Biol. Phys. 16: 1015-1019; 1989.
26. Beruhe, L. R.; Farah, S.; McClelland, R. A.; Rauth, A. M. Effect of l-methyl-2-nitrosoimidazole on intracellular thiols and calcium levels in Chinese hamster ovary cells. Biochem. Pharmacol. 42:2153-2161; 1991.
27. Cobb, L. M.; Connors, T. A.; Elson, L. A.; Khan, A. H.; Mitchley, B. C. V.; Ross, W. C. J.; Whisson, M. E. 2,4Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 18:1519-1527; 1969.
28. Roberts, J. J.; Friedlos, F.; Knox, R. J. CB 1954 (2,4-dinitro5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells. Biochem. Biophys. Res. Commun. 140:1073-1078; 1986.
29. Knox, R. J.; Boland, M. P.; Friedlos, F.; Coles, B.; Southan, C.; Roberts, J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 37:4671-4677; 1988.
30. Knox, R. J.; Friedlos, F.; Marchbank, T.; Roberts, J. J. Bioactivation of CB 1954: Reaction of the active 4hydroxylamino derivative with thioesters to form the ultimate DNA-DNA interstrand crosslinking species. Biochem. Pharmacol. 42:1691-1697; 1991.
31. Stratford, 1. J.; Williamson, C.; Hoe, S.; Adams, G. E. Radiosensitizing and cytotoxicity studies with CB 1954 (2,4dinitro-5-aziridinylbenzamide). Radiât. Res. 88:502-509; 1981.
32. Adams, G. E.; Ahmed, I.; Sheldon, P. W.; Stratford, I. J. RSU 1069, a 2-nitroimidazole containing an alkylating group: High efficiency as a radio- and chemosensitizer in vitro and in vivo. Int. J. Radiât. Oncol. Biol. Phys. 10:1653-1656; 1984.
33. Hill, R. P.; Gulyas, S.; Whitmore, G. F. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer 53:743-751; 1986.
34. Stratford, I. J.; Walling, J. M.; Silver, A. R. J. The differential cytotoxicity of RSU 1069: Cell survival studies indicating interaction with DNA as a possible mode of action. Br. J. Cancer 53:339-344; 1986.
35. Jenkins, T. C.; Naylor, M. A.; O'Neill, P.; Threadgill, M. D.; Cole, S.; Stratford, I. J.; Adams, G. E.; Fielden, E. M.; Suto, M. J.; Stier, M. A. Synthesis and evaluation of a-(((2haloethyl)amino)methyI)-2-nitro-lH-imidazole-1-ethanols as prodrugs of a-((l-aziridinyl)methyl)-2-nitro-lH-imidazole-lethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activated cytotoxins. J. Med. Chem. 33:2603-2610; 1990.
36. Whitmore, G. F.; Gulyas, S. Studies on the toxicity of RSU1069. Int. J. Radial. Oncol. Biol. Phys. 12:1219-1222; 1986.
37. Cole, S.; Stratford, I. J.; Bowler, J.; Nolan, J.; Wright, E. G.; Lorimore, S. A.; Adams, G. E. Oral (po) dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral (ip) administration in mice. Int. J. Radiât. Oncol. Biol. Phys. 21:387-395; 1991.
38. Adams, G. E.; Stratford, I. J. Bioreductive drugs for cancer therapy: The search for tumor specificity. Int. J. Radiât. Oncol. Biol. Phys. 29:231-238; 1994.
39. Parker, R. F.; Vincent, P. W.; Elliot, W. L. Alkylating property of nitro-imidazole radiosensitizers is required for induction of murine retinal degeneration. Vet. Pathol. 33:625; 1996.
40. Wilson, W. R.; van Zijl, P.; Denny, W. A. Bis-bioreductive agents as hypoxia-selective cytotoxins: Nitracrine N-oxide. Int. J. Radial. Oncol. Biol. Phys. 22:693-696; 1992.
41. Lee, H. H.; Wilson, W. R.; Ferry, D. M.; van Zijl, P.; Pullen, S. M.; Denny, W. A. Hypoxia-selective antitumor agents. 13. Effects of acridine substitution on the hypoxia-selective cytotoxicity and metabolic reduction of the bis-bioreductive agent nitracrine yV-oxide. J. Med. Chem. 39:2508-2517; 1996.
42. Hay, M. P.; Wilson, W. R.; Moselen, J. W.; Palmer, B. D.; Denny, W. A. Hypoxia-selective antitumour agents. 8. Bis-(nitroimidazolyl)alkanecarboxamides: A new class of hypoxia-selective cytotoxins and hypoxic cell radiosensitisers. J. Med. Chem. 37:381-391; 1994.
43. Moselen, J.; Hay, M.; Denny, W. A.; Wilson, W. R. N-(2-(2methyl-5-nitroimidazoIyl)ethyl)-4-(2-nitroimidazoIyl)butanamide (NNB, NSC 639862), a bis-bioreductive agent with marked selective toxicity towards hypoxic cells. Cancer Res. 55:574-580; 1995.
44. Denny, W. A.; Wilson, W. R. Bioreducible mustards: A paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Metastasis Rev. 12:135-151; 1993.
45. Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells. J. Med. Chem. 29:879-887; 1986.
46. Palmer, B. D.; Wilson, W. R.; Pullen, S. M.; Denny, W. A. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. Chem. 33: 112-121; 1990.
47. Palmer, B. D.; van Zijl, P.; Denny, W. A.; Wilson, W. R. Reductive chemistry of the novel hypoxia-selective cytotoxin 5-(N,N-bis(2-chloroethyl)amino)-2,4-dinitrobenzamide (SN 23862). J. Med. Chem. 38:1229-1241; 1995.
48. Lewis, D. F. V. Molecular orbital calculations on tumorinhibitory phenyl aziridines: QSARs. Xenobiotica 19:341-356; 1989.
49. Palmer, B. D.; Wilson, W. R.; Cliffe, S.; Denny, W. A. Hypoxia-selective antitumor agents. 5. Synthesis of watersoluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem. 35:3214-3222; 1992.
50. Hoy, C. A.; Thompson, L. H.; Mooney, C. L.; Salazar, E. P. Defective DMA cross-link removal in Chinese hamster cell mutants hypersensitive to bi functional alkylating agents. Cancer Res. 45:1737-1743; 1985.
51. Palmer, B. D.; Wilson, W. R.; Anderson, R. F.; Boyd, M.; Denny, W. A. Hypoxia-selective antitumor agents. 14. Synthesis and hypoxic cell cytotoxicity of regioisomers of the hypoxia-selective cytotoxin 5-(N,N-bis(2-chloroethyl)amino)2,4-dinitrobenzamide. J. Med. Chem. 39:2518-2528; 1996.
52. Anlezark, G. M.; Melton, R. G.; Sherwood, R. F.; Coles, B.; Friedlos, F.; Knox, R. J. The bioactivation of 5-(aziridin-lyl)-2,4-dinitrobenzamide (CB 1954) I. Purification and properties of a nitroreductase enzyme from Escherichia coli-a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT). Biochem. Pharmacol. 44:2289-2295; 1992.
53. van Osdol, W.; Fujimori, K.; Weinstein, J. N. An analysis of monoclonal antibody distribution in microscopic tumor nodules: Consequences of a "binding site barrier." Cancer Res. 51:4776-4784; 1991.
54. Springer, C. J.; Niculescu-Duvaz, I. Gene-directed enzyme prodrug therapy (GDEPT)-choice of produgs. Adv. Drug Delivery Rev. 22:351-364; 1996.
55. Friedlos, F.; Denny, W. A.; Palmer, B. D.; Springer, C. J. Mustard prodrugs for activation by E. coli nitroreductase in gene-directed enzyme-prodrug therapy (GDEPT). J. Med. Chem. 40:1270-1275; 1997.
56. Minton, N. P.; Mauchline, M. L.; Lemmon, M. J.; Brehm, J. K.; Fox, M.; Michael, N. P.; Giaccia, A.; Brown, J. M. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol. Rev. 17:357-364; 1995.
57. Dachs, G. U.; Stratford, I. J. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy. Br. J. Cancer 74(Suppl. XXVII):S126S132; 1996.
58. Knox, R. J.; Friedlos, F.; Sherwood, R. F.; Melton, R. G.; Anlezark, G. M. The bioactivation of 5-(aziridin-1-yI)-2,4dinitrobenzamide (CB1954)-II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase. Biochem. Pharmacol. 44:2297-2301; 1992.
59. Cliffe, S.; Thompson, K. M.; Palmer, B. D.; van Zijl, P.; Wilson, W. R. Identification of the major hypoxic metabolites of CB 1954 and its nitrogen mustard analogue, SN 23862, in Chinese hamster cells [Abstract]. 40th Annu. Meeting Radiat. Res. Soc., 1996:60.
60. Atwell, G. J.; Boyd, M.; Palmer, B. D.; Anderson, R. F.; Pullen, S. M.; Wilson, W. R.; Denny, W. A. Synthesis and evaluation of 4-substituted analogues of 5-(N,N-bis(2chloroethyl)amino)-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anticancer Drug Design 11:553-567; 1996.
61. Palmer, B. D.; Wilson, W. R.; Atwell, G. J.; Schultz, D.; Xu, X. Z.; Denny, W. A. Hypo.xia-selective antitumor agents. 9. Structure-activity relationships for hypoxia-selective cytotoxicity among analogues of 5-(N,N-bis(2-chloroethyI)amino)2,4-dinitrobenzamide. J. Med. Chem. 37:2175-2184; 1994.
62. Chaplin, D. J. Hydralazine-induced tumor hypoxia: A potential target for cancer chemotherapy. J. Natl. Cancer Inst. 81: 618-622; 1989.
63. Rewcastle, G. W.; Atwell, G. J.; Zhuang, L.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 61. Structureactivity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem. 34:217-222;1991.
64. Cliffe, S.; Taylor, M. L.; Rutland, M.; Baguley, B.; Hill, R. P.; Wilson, W. R. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxantherione acetic acid. Int. J. Radial. Oncol. Biol. Phys. 29:373-377; 1994.
65. Zwi, L. J.; Baguley, B. C.; Gavin, J. B.; Wilson, W. R. The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumor. Pathology 26:161-169; 1994.
66. Wilson, W. R.; Pruijn, F. B. Hypoxia-activated prodrugs as antitumour agents: Strategies for maximizing tumor cell killing. Clin. Exp. Pharmacol. Physiol. 22:881-885; 1995.
67. Vincent, P. W.; Roberts, B. J.; Elliot, W. L.; Leopold, W. R. Chemotherapy with DMXAA (5,6-dimethylxanthenone-4acetic acid) in combination with CI-1010 (IH-imidazole-lethanol,alpha-(((2-bromoethyl)amino)methyl)-2-nitro-, mono hydrobromide (R isomer)) against advanced stage murine colon carcinoma 26. Oncol. Rep. 4:143-147; 1997.
68. Pruijn, F. B.; van Daalen, M.; Holford, N. H. G.; Wilson, W. R. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour blood flow inhibitor 5,6dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 39:541-546; 1997.
69. Baguley, B. C.; Cole, G.; Thomsen, L. L.; Zhuang, L. Serotonin involvement in the antitumour and host effects of flavone8-acetic acid and 5,6-demethyIxanthenone-4-acetic acid. Cancer Chemother. Pharmacol. 33:77-81; 1993.
70. Pedley, R. B.; Boden, J. A.; Boden, R.; Boxer, G. M.; Flynn, A. A.; Keep, P. A.; Begent, R. H. J. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res. 56:3293-3300; 1996.
71. Chapman, J. D. Franko, A. J., Sharplin, J. A marker for hypoxic cells in tumours with potential clinical applicability. Br. J. Cancer 43:546-550; 1981.
72. Evans, S. M.; Joiner, B.; Jenkins, W. T.; Laughlin, K. M.; Lord, E. M.; Koch, C. J. Identification of hypoxia in cells and tissues of epiglastic 9L rat glioma using EF5 (2-(2-nitro-lH-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyI)acetamide). Br. J. Cancer 72:875-882; 1995.
73. Hodgkiss, R. J.; Webster, L.; Wilson, G. D. Development of bioreductive markers for tumour hypoxia. Acta Oncol. 34: 351-355;1995.
74. Firestone, A.; Mulcahy, R. T.; Borch, R. F. Nitroheterocycle reduction as a paradigm for intramolecular catalysis of drug delivery to hypoxic cells. J. Med. Chem. 34:2933-2935; 1991.
75. Mulcahy, R. T.; Gipp, J. J.; Schmidt, J. P.; Joswig, C.; Borch, R. F. Nitrobenzyl phosphoramidates as potential hypoxia-selective alkylating agents. J. Med. Chem. 37:1610-1615; 1994.
76. Denny, W. A.; Wilson, W. R.; Tercel, M.; Van Zijl, P.; Pullen, S. M. Nitrobenzyl mustard quaternary salts, a new
77. class of hypoxia-selcctive cytotoxin capable of releasing diffusible cytotoxins on bioreduction. Int. J. Radiât. Oncol. Biol. Phys. 29:317-321; 1994.
78. Neta, P.; Behar, D. Intramolecular electron transfer in the anion radicals of nitrobenzyl halides. J. Am. Chem. Soc. 102: 4798-4802; 1980.
79. Wilson, W. R.; Ferry, D. M.; Tercel, M.; Anderson, R. F.; Denny, W. A. Radiolytic reduction of nitro(hetero)aromatic methylquaternary (NMQ) prodrugsof mechlorethamine. Radial. Res. (in press).
80. Tercel, M.; Wilson, W. R.; Denny, W. A. Nitrobenzyl mustard quaternary salts: A new class of hypoxia-selective cytotoxins showing very high in vitro selectivity. J. Med. Chem. 36:2578-2579; 1993.
81. Tercel, M.; Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 12. Nitrobenzyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine. J. Med. Chem. 39:1084-1094; 1996.
82. Teicher, B. A.; Sartorelli, A. C. Nitrobenzyl halides and carbamates as prototype bioreductive alkylating agents. J. Med. Chem. 23:955-960; 1980.
83. Kirkpatrick, D. L.; Johnson, K. E.; Sartorelli, A. C. Nitrobenzyl derivatives as bioreductive alkylating agents: Evidence for
84. the reductive formation of a reactive intermediate. J. Med. Chem. 29:2048-2052; 1986.
85. Moreno, S. N. J.; Schreiber, J.; Mason, R. P. Nitrobenzyl radical metabolites from microsomal reduction of nitrobenzyl chlorides. J. Biol. Chem. 261:7811-7815; 1986.
86. Hay, M. P.; Wilson, W. R.; Denny, W. A. A novel enediyne prodrug for antibody-directed enzyme prodrug therapy (ADEPT) using E. co/i B nitroreductase. Bioorg. Med. Chem. Lett. 5:2829-2834; 1995.
87. Wilson, W. R.; Denny, W. A.; Tercel, M. Radiation-activated cytotoxins: A new use for Roentgen's rays in cancer treatment? In: Hagen, U.; Harder, D.; Jung, H.; Streffer, C., eds. Radiation research 1895-1995. Congress Proceedings. Wurzburg: 10th International Congress of Radiation Research; 1996:791-794.
88. Atwell, G. J.; Wilson, W. R.; Denny, W. A. Synthesis and cytotoxicity of novel amino analogues of the potent DNA alkylating agent seco-CBI-TMI. Bioorg. Med. Chem. Lett. 7: 1493; 1997.
89. Sum, B. G.; Atwell, G. J.; Wilson, W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino5-nitroquinoline bioreductive drugs. Br. J. Cancer 70:596-603; 1994.